Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$10.6MCash on Hand
10.1mo Cash Runway
Follow PHIO by emailGet an email when PHIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PHIO, unsubscribe in one click. Privacy
📣 What PHIO Says Is Next
first quarter of 2027 · PH-762: “The Company also announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing an important CMC (chemistry, manufacturing and controls) milestone that supports the planned Phase 2b clinical program, which is expected to be initiated in the first quarter of 2027.”
Company press release, Nov 5, 2026 · SEC filing
by the end of November 2026 · “The submission seeks FDA feedback on the proposed development strategy and next steps, with a response expected from the FDA by the end of November 2026.”
Company press release, Nov 5, 2026 · SEC filing
first quarter of 2027 · “Validated drug substance will now proceed through the final steps of drug product completion for use in Phio's planned Phase 2b clinical study, which is expected to be initiated in the first quarter of 2027.”
Company press release, Oct 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Reported Q3 2026 net loss of $4.2M versus $2.4M a year earlier, as R&D rose to $3.0M on PH-762 manufacturing and toxicology costs. Cash was $10.6M at September 30, 2026, down from $21.0M at December 31, 2025. The FDA is expected to respond to a briefing submission by end of November 2026. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 13, 2026 ·
Phio announced it released its first commercial-scale cGMP batch of PH-762 drug substance, a milestone it says supports planned initiation of a Phase 2b trial in the first quarter of 2027. Form 8-K · SEC filing · Press release
Sep 28, 2026 ·
Shareholder vote Stockholders approved a 1,500,000-share increase to the 2020 Long Term Incentive Plan, bringing total available shares to 2,452,017, and elected six directors and ratified Grant Thornton as auditor at the September 28, 2026 annual meeting. Form 8-K · SEC filing
Sep 14, 2026 ·
Regulatory Phio submitted a meeting request and briefing package to the FDA for PH-762 after completing its Phase 1b trial, covering a planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma. Clinical supplies are expected in Q1 2027. Form 8-K · SEC filing · Press release
Aug 14, 2026 ·
Shareholder vote Phio Pharmaceuticals will hold a virtual 2026 annual meeting on September 28, 2026. Stockholders will vote on electing six directors, ratifying Grant Thornton, LLP as auditor, and adding 1,500,000 shares to the 2020 Long Term Incentive Plan. The board recommends voting FOR all three proposals. Form DEF 14A · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1 · Active Trial · Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PHIO's own candidates): Interleukin-2.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PHIO holds $10.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.2M/quarter from operations,
an estimated runway of 10.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:77 · High
Cash runway 10 months +30
ATM program on file since Apr 2026 +15
Shelf registration (S-3, May 2024) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt regarding the Company's ability to continue as a going concern.10-Q, Nov 2026
Share count 11,951,632 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PHIO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHIO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.